GE HealthCare Technologies Inc. filings document formal disclosures for a medical technology and diagnostics company, including Form 8-K reports on results of operations and financial condition, material agreements, capital-structure matters, and governance changes. Recent current reports include earnings releases, a senior unsecured revolving credit facility, and board-related disclosures.
The company’s proxy materials describe annual-meeting matters, director elections, board committee assignments, executive compensation, equity awards, and shareholder voting procedures. GEHC filings also provide formal context for segment performance, liquidity arrangements, credit covenants, and governance matters tied to its healthcare technology, software, and pharmaceutical diagnostics businesses.
GE HealthCare Technologies Inc. director William J. Stromberg reported an open-market purchase of company stock. On May 6, 2026, he bought 1,000 shares of common stock at $61.6892 per share, bringing his directly held ownership to 15,330 shares after the transaction.
GE HealthCare Technologies Inc. executive Catherine Estrampes, Chief Commercial & Growth Officer, reports beneficial ownership of 24,081 shares of common stock. This includes 14,374 shares plus restricted stock units that may settle into additional shares as they vest.
She also holds multiple employee stock options on GE HealthCare common stock. These options cover underlying share amounts such as 16,398 shares at an exercise price of $80.16 expiring on March 2, 2036, and 9,923 shares at $86.45 expiring on March 3, 2035, along with several other grants with different prices and expirations.
GE HealthCare Technologies Inc. Chief Financial Officer James Saccaro purchased 3,310 shares of Common Stock in an open-market transaction on May 1, 2026 at a weighted average price of $60.5997 per share. Following this purchase, he directly owns 87,471 shares. The filing notes the shares were bought in multiple trades at prices ranging from $60.59 to $60.60 per share.
GE HealthCare Technologies Inc. General Counsel and Corporate Secretary Frank R. Jimenez reported an open-market purchase of 1,750 shares of common stock at a price of $60.45 per share. Following this transaction, he directly owns 93,932 shares of GE HealthCare common stock.
GE HealthCare Technologies Inc. President and CEO Peter J. Arduini made an open-market purchase of company stock. On this date, he bought 4,169 shares of common stock at $59.925 per share.
After this transaction, Arduini directly owns 259,424 shares of GE HealthCare common stock. This filing shows a net increase in his personal shareholding through a straightforward open-market purchase.
GE HealthCare Technologies Inc reported that Vanguard Capital Management beneficially owned 33,370,111 shares of common stock, representing 7.31% of the class as of 03/31/2026. The filing shows sole voting power for 4,505,923 shares and sole dispositive power for 33,370,111 shares, and includes a disclosure that ownership reflects holdings of Vanguard affiliates and managed funds.
GE HealthCare Technologies reported first‑quarter 2026 revenue of $5.13 billion, up from $4.78 billion a year earlier, driven by higher product and service sales across segments. Net income attributable to GE HealthCare fell to $389 million from $564 million as operating income declined to $515 million from $629 million, pressured in part by restructuring, acquisition‑related costs, and higher tariffs.
The company closed the $2.30 billion cash acquisition of Intelerad, adding significant imaging software capabilities and increasing goodwill and definite‑lived intangibles. Operating cash flow was $290 million, while investing activities used $2.50 billion, largely for Intelerad. GE HealthCare also repurchased $100 million of stock and ended the quarter with $2.29 billion in cash and $10.13 billion of borrowings.
GE HealthCare Technologies Inc. reported mixed first quarter 2026 results, combining solid revenue growth with weaker profitability and a reduced full‑year profit outlook.
Total revenues were $5.1 billion, up 7.4%, with Organic revenue growth of 2.9%, driven primarily by Pharmaceutical Diagnostics, Advanced Visualization Solutions, and Imaging across the U.S., EMEA, and Rest of World. Net income attributable to GE HealthCare fell to $389 million from $564 million, as net income margin declined to 7.6% from 11.8%. Adjusted EBIT was $691 million versus $715 million, with Adjusted EBIT margin at 13.5% compared with 15.0%. Diluted EPS was $0.85 versus $1.23, while Adjusted EPS was $0.99 versus $1.01.
Segment results were varied: Pharmaceutical Diagnostics revenue rose to $770 million with 9.7% Organic growth, but Patient Care Solutions revenue declined to $704 million with an 8.1% Organic decline and sharply lower EBIT. Management cited a discrete PDx supplier issue, higher memory chips, oil, and freight costs, and tariffs as margin headwinds, noting the PDx issue has been resolved.
Cash from operating activities was $290 million and Free cash flow was $112 million, both up year‑over‑year. The company closed the $2.3 billion Intelerad acquisition, ended the quarter with $2.3 billion of cash and cash equivalents, $10.1 billion of total debt, repurchased 1.4 million shares for $100 million, and declared a $0.035 per‑share dividend.
For full‑year 2026, GE HealthCare reaffirmed Organic revenue growth guidance of 3.0% to 4.0% but reduced profitability expectations. Adjusted EBIT margin guidance is now 15.4% to 15.7%, down from 15.8% to 16.1%. Adjusted EPS is guided to $4.80 to $5.00, versus prior guidance of $4.95 to $5.15, and Free cash flow is now expected to be approximately $1.6 billion versus prior guidance of approximately $1.7 billion. Management expects mid‑ to high‑single digit Adjusted EPS growth, assuming more pronounced inflation but partly offset by pricing and cost actions.
GE HealthCare Technologies Inc Schedule 13G/A amendment shows The Vanguard Group reporting 0 shares and 0% beneficial ownership of Common Stock as of the amendment. The filing notes an internal realignment on 01/12/2026 that led to disaggregated reporting by Vanguard subsidiaries.